Remove 2019 Remove Cannabis Remove Epilepsy Remove Pharmaceutical
article thumbnail

GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex

Cannabis Law Report

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older. TSC is typically diagnosed in childhood. (5)

article thumbnail

GW’s Cannabis-Based Epilepsy Drug Set For European Approval

Cannabis Law Report

Following an encouraging initial US launch, GW Pharmaceuticals’s cannabidiol oral solution is also set to achieve European approval later in 2019. Knowledge, attitudes and policies regarding medical cannabis and cannabis-based drugs are changing. Here are the takeaways ( Source Fitch). Source: [link].

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

BBC Report: EU Approves , “Epidyolex” GW Pharmaceuticals

Cannabis Law Report

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. Medical cannabis costs family £4,000 a month to help teenager.

article thumbnail

GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales

Cannabis Law Report

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. 14th at 11:00 a.m.

article thumbnail

Thailand: Press Release Thailand Govt Pharma Organization “Pharmaceutical Organization, Department of Medical Cooperation, Research on Medical Marijuana Extracts For cancer patients with neurodegenerative epilepsy And nervous pain”

Cannabis Law Report

Press Release: Thailand Government Pharmaceutical Organization. 30 May 2019. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths.

article thumbnail

Georgia Medical Cannabis Patients Can Now Purchase Cannabis Oil From Pharmacies

Veriheal

Georgia medical cannabis patients will soon have greater access to treatment as cannabis oil will be sold in many more pharmacies. The Georgia State Board of Pharmacy recently made the decision to endorse more cannabis oil sale outlets. Its conversion into low-THC cannabis oil also allowed for treating many diseases.

Oil 97
article thumbnail

Insys Development Company, Inc. v. GW Pharma Limited Co., Case No. IPR2017-00503 – PTAB Only Partially Smokes Cannabis Patent

Cannabis Law Report

January 2019. Eleven of thirteen cannabis patent claims survive PTAB challenge. filed a petition requesting inter partes review of claims 1-13 of GW Pharmaceutical Ltd.’s s patent directed to the use of cannabinoids, including cannabidiol (“CBD”), in the treatment of certain types of epilepsy. IPR2017-00503, Paper No.